Verified by AISci
Public source attached
Source status for this paper in the current AISci reviewed snapshot.
- Primary source
- ClinicalTrials.gov
- Correction status
- none
- Evidence coverage
- 1 sources / 1 publishers
- Last metadata check
- Jul 19, 2026
Pre-emptive Anakinra for Cytokine Event Reduction (NCT06703216)
Pre-emptive Anakinra for Cytokine Event Reduction | Phase: PHASE1 | Conditions: B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome
SourceClinicalTrials.govVerified by AISci
Source status for this paper in the current AISci reviewed snapshot.
AI Reading Notes
Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.
Research Workflow
Recommended next steps for turning this signal into research action.
No reviewed author edge is attached to this output.
No source-confirmed author affiliation is attached.
Controlled AISci Stage A topic for Protein and Drug Design.
Organization linked by public source evidence.
Clinical/translation signal: Pre-emptive Anakinra for Cytokine Event Reduction